Germany’s B. Braun has run afoul of regulators in Europe after an inspection last week of a warehouse in the Czech Republic found it was distributing products not on an approved list.
According to a post by the European Medicines Agency, the site in Rudná was inspected Jan. 17 by Czech regulators. They said it was found the warehouse didn't "comply with the Good Distribution Practice requirements,” the agency said. According to the post, the agency suspended the authorization for the warehouse and ordered the “immediate” transfer of the drugs to another approved facility.
Warehouse failings sometimes figure into regulatory issues. Last year the FDA issued a warning letter to a Chinese company that among many problems had a dirty warehouse. An Indian drugmaker was cited the before when inspectors found birds flying around the facility and a lizard was seen crawling around in a storage warehouse.
The Melsungen-based company has operations in 64 countries. Last summer it landed a $33 million loan from the International Finance Corporation (IFC), a member of the World Bank Group, to help fund the construction of a sterile injectables plant in Indonesia.